CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Combined use of a respiratory broad panel multiplex PCR and procalcitoninWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1212 Usual antibiotic treatment Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.07

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial

The novel coronavirus SARS-CoV-2 (COVID-19) is an emerging respiratory virus that causes pneumonia. WHO data reported admission to the intensive care unit (ICU) for 6% of patients, with a mortality rate reaching 45%. To date, apart from therapeutic trials, ICU management is symptomatic, based on organ failure support therapies. In the initial phase, the therapeutic management also includes empiric antimicrobial therapy (90% of patients, in accordance with LRTI guidelines (ATS 2019) and SRLF Guidelines (2020). One challenge for the ICU physicians is the timing for discontinuation of antimicrobial treatment, especially in case of shock or ARDS, considering that a substantial proportion of COVID-19 pneumonia patients may have pulmonary bacterial coinfection/superinfection. In order to avoid unnecessary prolonged antimicrobial therapy, and subsequent selective pressure, two tests could be combined in a personalized antibiotic strategy: - Procalcitonin (PCT): PCT is a useful tool to guide antibiotics discontinuation in community-acquired pneumonia) and viral pneumonia (PMID24612487). - Respiratory multiplex PCR FA-PPP (Biomérieux®): panel has been enlarged, including 8 viruses and 18 bacteria (quantitative analysis). The turnaround time is short. Sensitivity is high (99%, PMID32179139). It may contribute, in combination with conventional tests, to accelerate and improve the microbiological diagnosis during severe COVID-19 pneumonia. The hypothesize of the study is that the combination of the mPCR FA-PPP and PCT could be used to reduce antibiotics exposure in patients with severe confirmed COVID-19 pneumonia, with a higher clinical efficacy and safety as compared with a conventional strategy.

NCT04334850 Covid19 Pneumonia Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin Other: Usual antibiotic treatment

Primary Outcomes

Description: the number of days alive without any antibiotics at Day 28. The D28 time point is usual in studies assessing antibiotics saving in ICU patients.

Measure: Number of antibiotic free days

Time: Day 28

Secondary Outcomes

Measure: Mortality rates

Time: Day 28 and Day 90

Measure: Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.

Time: day 28

Description: Total exposure to antibiotics

Measure: Antibiotics duration at D28

Time: Day 28

Measure: Number of organ-failure free days (based on SOFA)

Time: Day 28

Measure: Incidence rates of bacterial super-infections

Time: day 28

Measure: Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections

Time: Day 28

Measure: ICU and hospital lengths of stay

Time: Day 28

Description: using a quality of life questionnaire (EQ5D5L)

Measure: Quality of life Quality of life

Time: Day 90

Related HPO nodes (Using clinical trials)